ADMA

The Week

Moderna (MRNA) fell 8.22% this week to close at $200.10, underperforming the S&P 500 by roughly 7.75 percentage points as the benchmark slipped 0.47%. The move was a rise-and-reversal: shares opened at $217.27 on Monday, climbed through Tuesday and Wednesday to a weekly high of $254.48, then dropped sharply on Thursday, touching $180.80 before closing at $202.63. Friday saw another leg lower to $200.10. Weekly amplitude reached 33.91%, with average daily volume of about 24.6 million shares running above the recent 60-day pace.

Key Events

The week’s main story was the Merck-Moderna personalised mRNA cancer vaccine data and a leak around it. Social media posts flagged a potential data leak before Thursday’s open, and the stock fell more than 17% in regular trading, with some put options surging as much as 23,400%. On Friday, Phase 3 results showed the vaccine reduced melanoma recurrence risk by 42%, yet the sell-off extended, with the stock down more than 8% intraday at one point. Mizuho’s Jared Holz said the decline reflected a high bar rather than bad data. ESMO said it could not establish the precise circumstances that led to the leak. Some commentary noted the real test for the cancer vaccine is long-term prevention of recurrence rather than the relative short-term reduction.

Analyst Ratings

Among brokers covering Moderna, 4 rate it buy, 1 overweight, 14 hold, 2 underweight and 2 sell, for 23 in total. The consensus rating is hold, with a consensus target of $135.84, about 32.1% below the spot price of $200.10. The target range is wide, from a low of $45.00 to a high of $251.00, pointing to a large spread in views. The stock ranks 22nd in ratings within its industry out of 511 names.

The Week Ahead

Moderna reports fiscal Q3 2026 results before the open on 6 November, with consensus estimates at a loss of $1.28 per share and revenue of $891 million. On the macro side, 26 October brings the Dallas Fed manufacturing activity index, followed on 27 October by durable goods orders, new home sales and consumer confidence. Investors will also watch how the market digests the cancer vaccine data and any further details on the leak.

In Short

Moderna’s drop this week coincided with the cancer vaccine data and leak, but the link is correlational rather than causal. On valuation, the stock trades at about 11.8x book value with negative earnings. Latest-session fund-flow data shows a net-inflow direction across large, medium and small orders, though the amounts are modest. Broker ratings skew neutral, with the consensus target below spot. The key follow-through is the 6 November earnings call for any update on cash flow or pipeline, and how the market reprices the long-term value of the cancer vaccine.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.